Title:
EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
Document Type and Number:
WIPO Patent Application WO2004014292
Kind Code:
A3
Abstract:
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
Inventors:
KINCH MICHAEL S (US)
CARLES-KINCH KELLY (US)
STEWART JANE C (US)
CARLES-KINCH KELLY (US)
STEWART JANE C (US)
Application Number:
PCT/US2003/015046
Publication Date:
February 16, 2006
Filing Date:
May 12, 2003
Export Citation:
Assignee:
PURDUE RESEARCH FOUNDATION (US)
MEDIMMUNE INC (US)
KINCH MICHAEL S (US)
CARLES-KINCH KELLY (US)
STEWART JANE C (US)
MEDIMMUNE INC (US)
KINCH MICHAEL S (US)
CARLES-KINCH KELLY (US)
STEWART JANE C (US)
International Classes:
C07K16/24; C07K16/28; C07K16/30; (IPC1-7): C12N15/12; C12N15/63; C12N5/10; C12N5/06; G01N33/53; G01N33/574; A61K39/395; C12P21/08; C07K16/00
Foreign References:
| US5747033A | 1998-05-05 | |||
| US5795734A | 1998-08-18 | |||
| US6063903A | 2000-05-16 | |||
| US5955291A | 1999-09-21 | |||
| US6555321B1 | 2003-04-29 | |||
| US6927203B1 | 2005-08-09 | |||
| US5766886A | 1998-06-16 | |||
| US6696550B2 | 2004-02-24 |
Other References:
TILLMAN D. ET AL.: "Both IgM and IgG Ati-DNA Antibodies Are the Products of Clonally Selective B Cell Stimulation in (NZB x NZW)FI Mice.", JOURNAL OF EXPERIMENTAL MEDICINE., vol. 176, September 1992 (1992-09-01), pages 761 - 779, XP002930986
CATON A. ET AL.: "Structural and Functional Implicaties of a restricted antibody response to a defined antigenic region on the influenzy virus hemagglutinin.", THE EMBO JOURNAL, vol. 5, no. 7, 1986, pages 1577 - 1587, XP002963047
OGAWA K. ET AL.: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumorneovascularization.", ONCEGENE., vol. 19, October 2000 (2000-10-01), pages 6043 - 6052, XP001024674
CATON A. ET AL.: "Structural and Functional Implicaties of a restricted antibody response to a defined antigenic region on the influenzy virus hemagglutinin.", THE EMBO JOURNAL, vol. 5, no. 7, 1986, pages 1577 - 1587, XP002963047
OGAWA K. ET AL.: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumorneovascularization.", ONCEGENE., vol. 19, October 2000 (2000-10-01), pages 6043 - 6052, XP001024674
Download PDF: